CL2016000436A1 - Método para el tratamiento de la enfermedad fibrótica - Google Patents

Método para el tratamiento de la enfermedad fibrótica

Info

Publication number
CL2016000436A1
CL2016000436A1 CL2016000436A CL2016000436A CL2016000436A1 CL 2016000436 A1 CL2016000436 A1 CL 2016000436A1 CL 2016000436 A CL2016000436 A CL 2016000436A CL 2016000436 A CL2016000436 A CL 2016000436A CL 2016000436 A1 CL2016000436 A1 CL 2016000436A1
Authority
CL
Chile
Prior art keywords
treatment
fibrotic disease
inhibitor
csf
colonies
Prior art date
Application number
CL2016000436A
Other languages
English (en)
Inventor
Diane Marshall
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CL2016000436A1 publication Critical patent/CL2016000436A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

INHIBIDOR DE LA ACTIVIDAD DE CSF-1R (RECEPTOR DEL FACTOR ESTIMULANTE DE COLONIAS 1); USO DEL INHIBIDOR PARA PREPARAR MEDICAMENTO ÚTIL PARA EL TRATAMIENTO DE LA ENFERMEDAD FIBRÓTICA; Y MÉTODO DE TRATAMIENTO DE ENFERMEDAD FIBRÓTICA.
CL2016000436A 2013-08-30 2016-02-25 Método para el tratamiento de la enfermedad fibrótica CL2016000436A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1315486.9A GB201315486D0 (en) 2013-08-30 2013-08-30 Antibodies

Publications (1)

Publication Number Publication Date
CL2016000436A1 true CL2016000436A1 (es) 2016-11-18

Family

ID=49397072

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000436A CL2016000436A1 (es) 2013-08-30 2016-02-25 Método para el tratamiento de la enfermedad fibrótica

Country Status (17)

Country Link
US (1) US20160200820A1 (es)
EP (1) EP3039041B1 (es)
JP (1) JP6618471B2 (es)
KR (1) KR102346566B1 (es)
CN (2) CN105612181A (es)
AU (1) AU2014314303B2 (es)
BR (1) BR112016004297B1 (es)
CA (1) CA2920931C (es)
CL (1) CL2016000436A1 (es)
ES (1) ES2786260T3 (es)
GB (1) GB201315486D0 (es)
IL (1) IL244042B (es)
MX (1) MX2016002179A (es)
MY (1) MY181808A (es)
RU (1) RU2016111619A (es)
SG (1) SG11201601149TA (es)
WO (1) WO2015028454A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
CA3005932A1 (en) * 2015-11-25 2017-06-01 Nogra Pharma Limited Il-34 antisense oligonucleotides and methods of using same
US20190083495A1 (en) * 2016-04-04 2019-03-21 Massachusetts Institute Of Technology Methods Of Preventing Or Reducing A Fibrotic Response Using CSF1R Inhibitors
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
JP7537874B2 (ja) 2017-05-19 2024-08-21 シンダックス ファーマシューティカルズ， インコーポレイテッド 併用療法
CN110575540B (zh) * 2018-06-07 2021-11-02 中山大学附属第六医院 Pdgf抑制剂用于制备治疗肠道炎症疾病的药物方面的用途
WO2020159243A1 (ko) 2019-01-30 2020-08-06 한양대학교 산학협력단 폐 섬유화 질환 진단 또는 치료를 위한, m-csf 또는 g-csf의 이용
KR102356829B1 (ko) * 2019-01-30 2022-01-28 주식회사 에프엔씨티바이오텍 폐 섬유화 질환 진단 또는 치료를 위한, m-csf 또는 g-csf의 이용
KR102179518B1 (ko) 2019-03-29 2020-11-17 주식회사 혜안 황산염 자극에 의한 고로슬래그 활성화 무기 결합재 제조방법
US11430112B2 (en) * 2019-05-24 2022-08-30 PharmaNest LLC Systems and methods for quantitative phenotyping of fibrosis
EP4073100A4 (en) 2019-12-09 2024-02-14 Syndax Pharmaceuticals, Inc. ANTIBODIES FOR TREATING CHRONIC GRAFT VERSUS HOST DISEASE
MX2023013563A (es) 2021-05-17 2023-11-29 Nogra Pharma Ltd Agentes antisentido de il-34 y metodos de uso de los mismos.
CN113350346B (zh) * 2021-06-01 2023-06-27 广西医科大学第一附属医院 长春新碱在预防或治疗心肌纤维化中的应用
WO2023091479A1 (en) * 2021-11-17 2023-05-25 AmMax Bio, Inc. Detection and treatment of idiopathic pulmonary fibrosis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276812A1 (en) * 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
WO2004011624A2 (en) * 2002-07-31 2004-02-05 Nucleonics, Inc. Double stranded rna structures and constructs, and methods for generating and using the same
GB0326393D0 (en) * 2003-11-12 2003-12-17 Ares Trading Sa Cytokine antagonist molecules
SI1853718T1 (sl) * 2005-02-15 2016-02-29 Duke University Protitelesa anti-CD19 in uporabe v onkologiji
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
JP2010500283A (ja) * 2006-05-31 2010-01-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー チロシンキナーゼ阻害剤を用いて炎症性疾患を治療する方法
US20080114007A1 (en) * 2006-10-31 2008-05-15 Player Mark R 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
MX2010001918A (es) * 2007-08-21 2010-03-11 Amgen Inc Proteinas enlazadas al antigeno humano de celula de cepa mcdonough de felino.
EP2241333A1 (en) * 2007-12-12 2010-10-20 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
WO2010012667A1 (en) * 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
JP5868996B2 (ja) * 2010-12-13 2016-02-24 アレイ バイオファーマ、インコーポレイテッド ＩＩＩ型受容体チロシンキナーゼ阻害剤としての置換Ｎ−（１Ｈ−インダゾール−４−イル）イミダゾ［１，２−ａ］ピリジン−３−カルボキサミド化合物
HK1200032A1 (en) * 2011-10-21 2015-07-31 Transgene Sa Modulation of macrophage activation
EP2812355A4 (en) * 2012-02-06 2016-03-02 Hoffmann La Roche COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS

Also Published As

Publication number Publication date
RU2016111619A3 (es) 2018-05-17
EP3039041B1 (en) 2020-03-04
IL244042A0 (en) 2016-04-21
SG11201601149TA (en) 2016-03-30
CA2920931A1 (en) 2015-03-05
JP2016529265A (ja) 2016-09-23
CA2920931C (en) 2022-09-06
AU2014314303B2 (en) 2019-11-21
EP3039041A2 (en) 2016-07-06
BR112016004297B1 (pt) 2020-11-17
AU2014314303A1 (en) 2016-03-17
RU2016111619A (ru) 2017-10-05
WO2015028454A2 (en) 2015-03-05
IL244042B (en) 2020-07-30
US20160200820A1 (en) 2016-07-14
CN116036267A (zh) 2023-05-02
KR102346566B1 (ko) 2021-12-31
GB201315486D0 (en) 2013-10-16
WO2015028454A3 (en) 2015-05-21
KR20160045891A (ko) 2016-04-27
CN105612181A (zh) 2016-05-25
JP6618471B2 (ja) 2019-12-11
ES2786260T3 (es) 2020-10-09
BR112016004297A2 (pt) 2017-10-17
MY181808A (en) 2021-01-07
MX2016002179A (es) 2016-06-06

Similar Documents

Publication Publication Date Title
CL2016000436A1 (es) Método para el tratamiento de la enfermedad fibrótica
MX2015003140A (es) Formulaciones de enzalutamida.
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
EA201690629A1 (ru) Соединения, которые представляют собой тройные агонисты, глюкагона, glp-1 и gip
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
MX381640B (es) Metodos y compuestos agonistas de gip.
AR089993A1 (es) Macrociclos peptidomimeticos
TR201808169T3 (tr) Rekombinant probiyotik bakteriler .
CL2016001895A1 (es) Compuestos
MA40076A (fr) Inhibiteurs de syk
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UA116920C2 (uk) Інгібітори fgfr4
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
UY33884A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX390051B (es) Antagonistas de ep4.
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma